Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients

Androgen deprivation therapy (ADT) is first‐line palliative treatment in androgen receptor‐positive (AR+) salivary duct carcinoma (SDC), and response rates are 17.6–50.0%. We investigated potential primary ADT resistance mechanisms for their predictive value of clinical benefit from ADT in a cohort...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Cancer
Autori principali: van Boxtel, Wim, Verhaegh, Gerald W., van Engen‐van Grunsven, Ilse A., van Strijp, Dianne, Kroeze, Leonie I., Ligtenberg, Marjolein J., van Zon, Hans B., Hendriksen, Yara, Keizer, Diederick, van de Stolpe, Anja, Schalken, Jack A., van Herpen, Carla M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2019
Soggetti:
Tumor Markers and Signatures
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7187215/
https://ncbi.nlm.nih.gov/pubmed/31745978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32795
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi